{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:55:36Z","timestamp":1790366136519,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.vaccine.2019.03.044","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T14:37:06Z","timestamp":1553697426000},"page":"2322-2330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine"],"prefix":"10.1016","volume":"37","author":[{"given":"Sanghita","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Piepenbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhubanti","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juilee","family":"Thakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann J.","family":"Hessell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-9575","authenticated-orcid":false,"given":"Nancy L.","family":"Haigwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Kobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.03.044_b0005","unstructured":"Joint United Nations Programme on HIV\/AIDS. Miles to go. Global AIDS update 2018. Geneva, Switzerland: Joint United Nations Programme on HIV\/AIDS; 2018. http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/miles-to-go_en.pdf."},{"key":"10.1016\/j.vaccine.2019.03.044_b0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1874613601610010034","article-title":"HIV infection and AIDS in Sub-Saharan Africa: current status, challenges and opportunities","volume":"10","author":"Kharsany","year":"2016","journal-title":"Open AIDS J"},{"key":"10.1016\/j.vaccine.2019.03.044_b0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.chom.2012.09.008","article-title":"A blueprint for HIV vaccine discovery","volume":"12","author":"Burton","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2019.03.044_b0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.03.044_b0025","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1128\/JVI.02419-10","article-title":"Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies","volume":"85","author":"Malherbe","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/515613","article-title":"First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response","volume":"178","author":"MacGregor","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.044_b0035","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.044_b0040","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.vaccine.2019.03.044_b0045","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI62423","article-title":"Alarmins: awaiting a clinical response","volume":"122","author":"Chan","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2019.03.044_b0050","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-13-2729","article-title":"Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity","volume":"74","author":"Villarreal","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2019.03.044_b0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coi.2014.03.004","article-title":"Interleukin 33: a switch-hitting cytokine","volume":"28","author":"Villarreal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.coi.2005.06.002","article-title":"Alarmins: chemotactic activators of immune responses","volume":"17","author":"Oppenheim","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0065","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1080\/21645515.2015.1026499","article-title":"Alarmin IL-33 elicits potent TB-specific cell-mediated responses","volume":"11","author":"Villarreal","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.03.044_b0070","doi-asserted-by":"crossref","first-page":"12703","DOI":"10.1128\/JVI.01182-10","article-title":"Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus","volume":"84","author":"Kayamuro","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0075","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1016\/j.vaccine.2015.03.086","article-title":"Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model","volume":"33","author":"Villarreal","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.044_b0080","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1073\/pnas.95.12.6930","article-title":"T1\/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function","volume":"95","author":"Lohning","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.03.044_b0085","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.4049\/jimmunol.0900328","article-title":"IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production","volume":"183","author":"Schneider","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0090","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0095","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.179.4.2051","article-title":"Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells","volume":"179","author":"Allakhverdi","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0100","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.4049\/jimmunol.1002103","article-title":"IL-33 activates B1 cells and exacerbates contact sensitivity","volume":"186","author":"Komai-Koma","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.03.044_b0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaut.2014.01.032","article-title":"IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut","volume":"50","author":"Sattler","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2019.03.044_b0115","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3899\/jrheum.100184","article-title":"Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis","volume":"37","author":"Mu","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0120","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1073\/pnas.1213713110","article-title":"Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies","volume":"110","author":"Pujanauski","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.03.044_b0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/vim.2010.0061","article-title":"The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization","volume":"23","author":"Peachman","year":"2010","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0130","doi-asserted-by":"crossref","first-page":"F5","DOI":"10.1097\/QAD.0000000000001857","article-title":"Anti-HIV IgM protects against mucosal SHIV transmission","volume":"32","author":"Gong","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2019.03.044_b0135","doi-asserted-by":"crossref","first-page":"e2274","DOI":"10.1371\/journal.pntd.0002274","article-title":"Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans","volume":"7","author":"Puschnik","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.03.044_b0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.vaccine.2009.09.086","article-title":"The smallpox vaccine induces an early neutralizing IgM response","volume":"28","author":"Moyron-Quiroz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.044_b0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/imr.12094","article-title":"How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth","volume":"255","author":"Baumgarth","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2019.03.044_b0150","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1084\/jem.20080979","article-title":"Dual role for B-1a cells in immunity to influenza virus infection","volume":"205","author":"Choi","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.03.044_b0155","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.20111696","article-title":"A germinal center-independent pathway generates unswitched memory B cells early in the primary response","volume":"209","author":"Taylor","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.03.044_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0165","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/IAI.71.5.2498-2507.2003","article-title":"Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A","volume":"71","author":"Martin","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.03.044_b0170","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.168.2.926","article-title":"Monophosphoryl lipid A activates both human dendritic cells and T cells","volume":"168","author":"Ismaili","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0175","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/12.6.807","article-title":"The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells","volume":"12","author":"De Becker","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0180","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.044_b0185","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/21645515.2015.1011019","article-title":"Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae","volume":"11","author":"O'Ryan","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.03.044_b0190","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1073\/pnas.1121627109","article-title":"Antigen-specific memory in B-1a and its relationship to natural immunity","volume":"109","author":"Yang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.03.044_b0195","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.1128\/JVI.01816-14","article-title":"Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1","volume":"88","author":"Sather","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0200","doi-asserted-by":"crossref","first-page":"e0209437","DOI":"10.1371\/journal.pone.0209437","article-title":"Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth","volume":"13","author":"Chukwuma","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.03.044_b0205","doi-asserted-by":"crossref","first-page":"12949","DOI":"10.1128\/JVI.01812-14","article-title":"Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits","volume":"88","author":"Malherbe","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0210","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.4049\/jimmunol.1500527","article-title":"Achieving potent autologous neutralizing antibody responses against Tier 2 HIV-1 viruses by strategic selection of envelope immunogens","volume":"196","author":"Hessell","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0215","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/JVI.77.4.2310-2320.2003","article-title":"Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region","volume":"77","author":"Srivastava","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0220","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.vaccine.2009.10.028","article-title":"Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection","volume":"28","author":"Sellhorn","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.044_b0225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jviromet.2015.02.016","article-title":"Development of an avidity assay for detection of recent HIV infections","volume":"217","author":"Shepherd","year":"2015","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.03.044_b0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ab.2011.07.007","article-title":"Important parameters for evaluation of antibody avidity by immunosorbent assay","volume":"418","author":"Dimitrov","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2019.03.044_b0235","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1038\/s41598-018-22307-8","article-title":"A highly potent and broadly neutralizing H1 influenza-specific human monoclonal antibody","volume":"8","author":"Nogales","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.03.044_b0240","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.03.044_b0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/vaccines2010089","article-title":"Recent developments in preclinical DNA vaccination","volume":"2","author":"Okuda","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2019.03.044_b0250","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4049\/jimmunol.158.2.816","article-title":"In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen","volume":"158","author":"Kim","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0255","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1128\/JVI.72.6.4931-4939.1998","article-title":"Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes","volume":"72","author":"Sasaki","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virol.2005.10.038","article-title":"Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime\/protein boost HIV-1 vaccine","volume":"346","author":"Cristillo","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.03.044_b0265","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2119\/molmed.2011.00428","article-title":"Interleukin-33 ameliorates experimental colitis through promoting Th2\/Foxp3(+) regulatory T-cell responses in mice","volume":"18","author":"Duan","year":"2012","journal-title":"Mol Med"},{"key":"10.1016\/j.vaccine.2019.03.044_b0270","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1182\/bloodadvances.2018019919","article-title":"B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33","volume":"2","author":"Arima","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2019.03.044_b0275","doi-asserted-by":"crossref","first-page":"13146","DOI":"10.1038\/srep13146","article-title":"IL-33 released by alum is responsible for early cytokine production and has adjuvant properties","volume":"5","author":"Rose","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.03.044_b0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2901","article-title":"The double life of a B-1 cell: self-reactivity selects for protective effector functions","volume":"11","author":"Baumgarth","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2018.01.001","article-title":"Control of B-1a cell development by instructive BCR signaling","volume":"51","author":"Kreslavsky","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0290","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-065X.2000.imr017515.x","article-title":"B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a \u201cnatural immune memory\u201d","volume":"175","author":"Martin","year":"2000","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2019.03.044_b0295","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1074-7613(01)00129-7","article-title":"Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens","volume":"14","author":"Martin","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.03.044_b0300","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.4049\/jimmunol.174.10.6532","article-title":"Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis","volume":"174","author":"Carbonari","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0305","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.molimm.2006.07.302","article-title":"Direct impact of inactivated HIV-1 virions on B lymphocyte subsets","volume":"44","author":"Viau","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0310","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.4049\/jimmunol.1203058","article-title":"Primate B-1 cells generate antigen-specific B cell responses to T cell-independent type 2 antigens","volume":"190","author":"Yammani","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0315","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.immuni.2004.06.019","article-title":"B1b lymphocytes confer T cell-independent long-lasting immunity","volume":"21","author":"Alugupalli","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.03.044_b0320","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.coi.2011.03.004","article-title":"T cell-independent B cell memory","volume":"23","author":"Defrance","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0325","first-page":"2821","article-title":"The main peritoneal source of precursors of the murine intestinal IgA plasma cell","volume":"16","author":"Kim","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2019.03.044_b0330","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.4049\/jimmunol.1101990","article-title":"Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens","volume":"187","author":"Haas","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.044_b0335","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1182\/blood-2009-01-200014","article-title":"The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells","volume":"114","author":"Taillardet","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2019.03.044_b0340","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.03.044_b0345","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design","volume":"11","author":"Sharma","year":"2015","journal-title":"Cell Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:30:58Z","timestamp":1759401058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19303780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":69,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0264410X19303780"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}